DE SB182

Allows drug manufacturers, their agents, and wholesalers to distribute dialysate drugs and devices directly to home dialysis patients with end-stage renal disease without requiring a pharmacy license

Requires dialysate drugs and devices to be FDA-approved, held by entities properly registered with the Board of Pharmacy as manufacturers or wholesalers, and delivered in original sealed packaging

Mandates that delivery may only occur upon receipt of a valid prescription from a practitioner

Permits delivery directly to patients (or their designees) for self-administration or to health care providers and institutions for administration of dialysis therapy